Site fees are the least standardized, most inconsistently named part of any CTA and Start-up is where it gets worst. Here's how to break black-box start-up fees into specific, verifiable activities you can actually evaluate.
If you've built an observational study budget, you know it's one of the simpler builds you'll encounter - lean SOEs, no IP administration, no PK draws. But why do these studies exist at all, and why does a drug that just finished a multi-thousand-patient Phase III program need more data collected on it? This article breaks down the logic behind observational research, the different study types you'll encounter, and what it actually means for the work on your desk.
Take one protocol, hand it to three experienced budget analysts, and ask each of them to build a study budget independently. You'll get three defensible grids - each internally consistent, each arguably correct, each slightly different. None of them are wrong. That's exactly the problem AI is about to make impossible to ignore.
AI is not eliminating clinical trial budget analyst roles - it is changing them. As protocol-to-budget automation improves, the profession is increasingly dividing into two distinct paths: reviewers who validate AI-generated budgets and strategists who focus on FMV, negotiations, country-specific costs, and stakeholder management.
This article breaks down the real skills behind career progression at every level - from becoming reliable as a junior analyst to driving strategy and influence at the lead and principal level.
Observational studies are often misunderstood in clinical trial budgeting. This article explains how to scope observational and non-interventional study budgets correctly, what costs should always be included, when additional procedures need to be coded, and how to handle common edge cases that create confusion during budget build.
Why do sponsors use central labs instead of local site laboratories? This article explains the real reason behind the central lab model in clinical trials, how it improves data consistency across global studies, the operational burden it creates at the site level, and why it matters for clinical trial budgeting and contract negotiations.
Central vs. local lab assumptions are one of the fastest ways to either overbuild or underbuild a clinical trial budget. This article breaks down how to code each setup correctly, how mixed lab models should be handled, and which assumptions must be documented to avoid costly rework, sponsor pushback, and site payment issues.
Protocol amendments are an inevitable reality of clinical research, not a reflection of budgeting errors. This guide explores how to distinguish between simple and complex amendments, manage the impact on site contracts, and execute a methodical "Delta Analysis" to keep your study on track.
Understanding UK clinical trial budgets starts with the time-based costing model. Unlike fixed-fee systems, each procedure is broken down by staff role and time allocation, often resulting in multiple line items for a single activity. Combined with mandatory uplifts such as indirect costs, capacity building, and Market Forces Factor (MFF), this structure can significantly increase the true cost per patient compared to initial estimates.
